Form 4: Arcutis Biotherapeutics CEO Todd Watanabe Sells Shares to Cover Tax Obligations

Arcutis Biotherapeutics CEO Todd Watanabe sold 19,301 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Todd Franklin Watanabe, CEO of Arcutis Biotherapeutics, sold 19,301 shares of common stock on February 3, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on January 12, 2024.
• These RSUs vest annually, with 25% vesting each year beginning on February 1, 2025, contingent upon Watanabe's continued service to the company.
• The shares were sold at a weighted average price of $12.7, with individual transactions ranging from $12.545 to $13.0096.
• Following the transaction, Watanabe directly owns 804,129 shares.
• Watanabe also has indirect ownership through various trusts and an LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine stock sale for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This sale appears to be a standard transaction to cover tax obligations related to equity compensation.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Arcutis Biotherapeutics, Todd Watanabe, stock sale, Form 4, RSUs, tax obligations, insider trading, ARQT